Healthcare / Medical DevicesKOSDAQ
$5610.00
-950.00 (-14.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-11.7B · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$21.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-115.2%
↓Gross Margin
22.0%
↓Debt/Equity
1.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.9%
FCF CAGR
—
FCF margin
-56.6%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.48B · net income $-6.59B · FCF $-4.80B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.48B | $8.48B | $10.14B | $12.92B | $13.31B |
| Net Income | $-6.59B | $-6.59B | $-20.78B | $-18.79B | $-17.68B |
| EBITDA | $-3.75B | $-3.75B | $-16.60B | $-14.92B | $-15.85B |
| EPS | -1913.00 | -1913.00 | -91460.00 | -9990.00 | -10950.00 |
| Gross Margin | 22.0% | 22.0% | -10.7% | 9.7% | 3.8% |
| Operating Margin | -89.6% | -89.6% | -174.2% | -159.3% | -130.4% |
| Net Margin | -77.6% | -77.6% | -205.0% | -145.5% | -132.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.64 | 1.64 | 3.26 | 2.39 | 2.06 |
| Current Ratio | 0.96 | 0.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.80B | $-4.80B | $-11.70B | $-24.01B | $-28.12B |
| Returns | |||||
| ROE | -115.2% | -115.2% | -459.1% | -232.6% | -188.7% |
| Valuation | |||||
| P/B | 3.76 | 3.76 | 7.03 | 9.34 | 10.22 |
| Growth & Yield | |||||
| Revenue Growth | -16.3% | -16.3% | -21.5% | -2.9% | — |
| EPS Growth | 97.9% | 97.9% | -815.5% | 8.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-91460.00 → -1913.00
Residual
-47.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.